Search
SOLACI Congress
HomeFilePharmacology

Pharmacology

View Category

Antithrombotic Anticoagulants

Looking for the best anti-aggregation scheme after TAVI

Original title: Comparison of Two Antiplatelet Therapy Strategies in Patients Undergoing Transcatheter Aortic Valve Implantation. Reference: Eric Durand et...
solaci -
Learn More
Acute coronary syndromes

Bivalirudin, effective in the pre-hospitalization phase of infarction

Original title: Bivalirudin Started during Emergency Transport for Primary PCI. Reference: Philippe G. Steg, et;al. NEJM 2013; Octubre 30:1-11Primary PCI...
solaci -
Learn More
Acute coronary syndromes

Low cardiac mortality with bivalirudin beyond the reduction in major bleeding

Original title: Reduction in Cardiac Mortality with Bivalirudin in Patients With and Without Major Bleeding: The HORIZONS-AMI Trial. Reference: Gregg...
solaci -
Learn More
Acute coronary syndromes

Infarct size reduction to 30 days could result in clinical benefit at one year

Original title: Intralesional abciximab and thrombus aspiration in patients with large anterior myocardial infarction: One-year results from the...
solaci -
Learn More
Antithrombotic Anticoagulants

Cilostazol reduces restenosis of DES in lesions larger than 40 mm.

Original title: Comparison of Dual Versus Triple Antiplatelet Therapy After Drug-Eluting Stent According to Stent Length (from the...
solaci -
Learn More
Acute coronary syndromes

Ticagrelor effective in venous bridges

Original title: Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass grafo surgery: Inssights...
solaci -
Learn More
Antiplatelet

Enoxaparin appears superior to unfractionated heparin in patients undergoing primary angioplasty

Original title: A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the...
solaci -
Learn More
Acute coronary syndromes

Ticagrelor reduces in-stent thrombosis in patients with acute coronary syndromes

Original title: Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: An analysis from the...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Long-Term Cardiovascular Risk in Patients With ANOCA: A Clinical Reality to Consider?

Dr. Omar Tupayachi - 0
Chronic stable angina (CSA) remains one of the most frequent reasons for referral to diagnostic coronary angiography (CAG). In a substantial proportion of these...

Perforation Management in Bifurcations: Bench Testing of Bailout with Covered Stents

Dr. Omar Tupayachi - 0
Coronary perforations during PCI are one of the most dreaded complications in interventional cardiology, especially in bifurcations. Though rate, this critical situation requires an...

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Dr. Omar Tupayachi - 0
Moderate to severe mitral valve regurgitation (MR) continues is still a high prevalence condition with bad prognosis, particularly among the elderly with left ventricular...

Institutional News

SOLACI Wishes You Happy Holidays

solaci - 0
From the heart, Happy Holidays! The Latin American Society of Interventional Cardiology wishes all its members and the medical community across the continent a very Merry Christmas...

Condolences on the passing of Cristiam Arancibia

solaci - 0
The Latin American Society of Interventional Cardiology deeply mourns the passing of Lic. Cristiam Arancibia, first Director of the Chapter of Technicians and Nurses,...

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy